AstraZeneca Results Presentation Deck
Calquence and Enhertu
Strong launch trajectories continue
17
$m
400
350
300
250
200
150
100
50
0
Calquence: 146% growth to $843m
Approvals/Reimbursements: 70/20 (CLL), 34/13 (MCL)
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
2019
2020
US Europe EROW EM
2021
• Global $843m; US $752m
• US CLL
New patient share of 52% in 1st-
line BTKI class and 20% overall ¹
●
Global CLL
Germany and UK largest growth
contributors. Successful launches
inc. France and Spain
• US MCL
Preferred BTKI in relapsed
refractory MCL
Se M
CALQUENCE
Watendinte caps
100 mg
Am
$m
80
60
40
20
0
Enhertu: 134% growth to $147m
Approvals/Reimbursements: 9/4 (BC), 4/2 (GC)
Q1 Q2 Q3 Q4
2020
US Europe EROW EM
Q1
Q2
2021
CLL = chronic lymphocytic leukaemia; MCL = mantle cell lymphoma; BTKI = Bruton tyrosine kinase inhibitor; GC = gastric cancer; 3L = 3rd-line. 1. IQVIA US ALPD Claims data NPS data to Sep-21.
Q3
●
●
Total revenue: Global $147m; US
$120m
Total in-market sales ex-Japan:
$293m
• US
#1 in 3rd-line HER2+ breast
cancer, strong launch in 2nd-line
gastric cancer
Global
Strong launch in France
continues
#1 in all
countries
launched
in 3L HER2+
mBC
ENHERTU
(am rasturnab denotecan-mok)
For Injection
100 mg per vial
For en ny
P
Perry
CATORN
KEEP REFRIGERATED
THE
gam
Daichi Sankyo AdtraZenecaView entire presentation